SGO Winter Meeting | Conference

Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer

February 11th 2020

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

Role of PARP Inhibition Shifts in Ovarian Cancer as Research Efforts Expand

February 11th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

Dr. Backes on Experience With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

Dr. Secord on Financial Toxicity Associated With PARP Inhibition

February 10th 2020

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Secord Shares Data to Digest With PARP Inhibitors in Ovarian Cancer

February 10th 2020

Three pivotal clinical trials evaluating PARP inhibitors have significantly impacted the treatment of patients with newly diagnosed ovarian cancer.

Dr. Hagemann on Best Practices for Pathology in Gynecologic Cancers

February 9th 2020

Ian Hagemann, MD, PhD, discusses the main take home from his presentation at the 2020 SGO Winter Meeting.

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

February 9th 2020

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Immunotherapy Shows Promise in Cervical Cancer Treatment

February 9th 2020

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

February 9th 2020

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Dr. Langstraat on Sentinel Lymph Nodes for Endometrial Cancer

February 9th 2020

Carrie L. Langstraat, MD, gynecologic oncologist, Mayo Clinic, discusses the role of sentinel lymph nodes in patients with endometrial cancers.